Fever-Tree H1 shares fall as U.S. margin pressure offsets profit beat

Fever-Tree reported first-half adjusted revenue of £184.2 million and EBITDA of £20.1 million, ahead of Jefferies forecasts of £182.2 million and £19.5 million, respectively, while EBITDA rose 9% year-on-year. U.S. revenue increased 11% at constant currency, but U.S. EBITDA margin contracted 190bps to 6.2% due to elevated marketing investment under the Molson Coors partnership, contributing to a share-price decline of more than 5%. Management maintained its FY2026 outlook, Jefferies retained its £400.7 million sales and £50.1 million EBITDA forecasts, and the company expanded its 2026 buyback authorization to £60 million.

Analysis

FEVR’s selloff creates a narrow execution opportunity rather than a clean earnings beat: the relevant signal is whether the Molson Coors distribution transition converts accelerating retail velocity into profitable replenishment. Marketing is being expensed ahead of scale, while the partner guarantee limits near-term downside; if U.S. sales growth remains in the mid-teens over the next two quarters, incremental distribution and fixed-cost absorption should drive a disproportionate recovery in segment margin during FY27. The market is likely discounting the current margin print rather than the lag between consumer activation and distributor economics.

TAP is a modest second-order beneficiary if premium mixer growth improves its route-to-market utilization and strengthens its credibility as an alcohol-adjacent beverage platform. Financial impact is immaterial to TAP at the group level, so it is not an earnings trade; the more relevant read-through is whether its network can win premium non-alcoholic and at-home occasion brands without requiring incremental fixed investment.

The key risk is that velocity growth reflects promotional or marketing intensity rather than durable household penetration. A failure of U.S. growth to sustain above 10% through the next reported period, further margin erosion despite the guarantee, or a reduction in FY26 EBITDA expectations would invalidate the operating-leverage thesis. The packaging dispute and reduced cash balance also matter because continued buybacks could constrain flexibility if working capital or marketing needs rise; the provision is not investable upside until formally resolved.

Contrarian view: the share reaction may be underestimating a self-funded margin trough, but buyback support should not be confused with organic valuation support. The next 1-3 months lack a major fundamental catalyst beyond channel data; the more meaningful rerating window is the FY26 results/FY27 outlook, when management must demonstrate that U.S. growth survives lower incremental marketing intensity.

Key Decisions for Investors

• Watchlist FEVR (London-listed): accumulate only after evidence of sustained U.S. retail growth above 10% and no cut to FY26 EBITDA expectations; target a 6-12 month recovery trade into visible U.S. margin normalization, with exit if U.S. segment profitability deteriorates again despite the Molson Coors guarantee.
• Do not treat TAP as a direct sympathy long. Maintain existing TAP exposure only if core beer margin and volume data independently support it; Fever-Tree distribution is strategically interesting but too small to move consensus estimates.
• For a relative-value consumer trade, consider long FEVR versus a short broad UK consumer-staples proxy only after the next U.S. channel-data update confirms velocity persistence. The thesis is company-specific operating leverage, not a broad defensive-consumer beta call.
• Set alerts for: FY26 EBITDA guidance change, U.S. segment margin trajectory, disclosed buyback completion/cash balance, and resolution of the packaging classification dispute. Any combination of weaker guidance and further cash depletion should shift FEVR from buy-the-dip candidate to avoid.